Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Non-Controlling Interests: 2022-2024

Historic Income from Non-Controlling Interests for Gyre Therapeutics (GYRE) over the last 3 years, with Dec 2024 value amounting to $5.8 million.

  • Gyre Therapeutics' Income from Non-Controlling Interests rose 34.30% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 0.19%. This contributed to the annual value of $5.8 million for FY2024, which is 22.00% down from last year.
  • Per Gyre Therapeutics' latest filing, its Income from Non-Controlling Interests stood at $5.8 million for FY2024, which was down 22.00% from $7.5 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Income from Non-Controlling Interests ranged from a high of $7.5 million in FY2023 and a low of $2.0 million during FY2022.
  • In the last 3 years, Gyre Therapeutics' Income from Non-Controlling Interests had a median value of $5.8 million in 2024 and averaged $5.1 million.
  • Per our database at Business Quant, Gyre Therapeutics' Income from Non-Controlling Interests surged by 270.43% in 2023 and then declined by 22.00% in 2024.
  • Over the past 3 years, Gyre Therapeutics' Income from Non-Controlling Interests (Yearly) stood at $2.0 million in 2022, then surged by 270.43% to $7.5 million in 2023, then fell by 22.00% to $5.8 million in 2024.